VANCOMYCIN 250 mg capsules

This tender concerns the procurement of Vancomycin 250 mg capsules. Vancomycin is a critical glycopeptide antibiotic primarily used to treat serious infections caused by Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). It is often reserved for severe infections or when other antibiotics are ineffective or contraindicated. The capsules are typically administered orally for intestinal infections, such as Clostridium difficile colitis, or intravenously for systemic infections. The tender likely seeks to secure a supply of this essential medication for healthcare facilities, potentially hospitals, clinics, or public health programs. Key requirements would typically include adherence to stringent quality standards, such as Good Manufacturing Practices (GMP), and compliance with relevant pharmacopoeial specifications (e.g., European Pharmacopoeia, USP). Suppliers may be required to provide detailed product specifications, batch certificates, and evidence of regulatory approval in the relevant jurisdiction. The tender may also specify packaging requirements, shelf-life, and delivery timelines. The procurement aims to ensure the availability of Vancomycin 250 mg capsules to meet patient needs and maintain effective treatment protocols for serious bacterial infections within the specified healthcare system.

This is a supplies contract in the health and medical services sector, with a focus on Pharmaceuticals. Located in Romania, Europe, this opportunity is open to firms and consortiums.

Published through TED - Tenders Electronic Daily (EU), a national government procurement portal. Public procurement tenders follow the country's national bidding regulations and may have specific eligibility and documentation requirements for the supply of goods in the health and medical services sector. Supply contracts typically require bidders to demonstrate product compliance with technical specifications, delivery capacity, and relevant certifications. This contract has already been awarded. The information is published for transparency and market intelligence purposes.